MedTrace Logo

MLD10 for the Treatment of Hypomagnesemic Patients With Type 2 Diabetes Mellitus

NCT03567824 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2023-11-27

No results posted yet for this study

Summary

To determine the effect of MLD10 (magnesium L-lactate dihydrate extended-release caplets) 10 mEq BID on serum magnesium in Type 2 diabetic patients with hypomagnesemia.

Conditions

  • Hypomagnesemia in Type 2 Diabetic Patients

Interventions

DRUG

Magnesium L-lactate dihydrate

Magnesium L-lactate dihydrate 10 mEq extended release caplets

DRUG

Placebo Oral Tablet

Placebo will have the same appearance, taste, odor and mode of administration as MLD10.

Sponsors & Collaborators

  • Pharmalyte Solutions LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-01
Primary Completion
2028-04-30
Completion
2028-04-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03567824 on ClinicalTrials.gov